Patents Examined by Craig D Ricci
  • Compositions and methods for the treatment of pain
    Patent number: 10987365
    Abstract: The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: April 27, 2021
    Assignee: GM Pharmaceuticals, Inc.
    Inventor: Odes W. Mitchell
  • Methods and compositions for the treatment of seizure-related disorders
    Patent number: 10987324
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 27, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
    Patent number: 10973835
    Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 13, 2021
    Assignees: The Penn State Research Foundation, Cold Spring Harbor Laboratory
    Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
  • Methods and compositions for the treatment of seizure-related disorders
    Patent number: 10973783
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 13, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
    Patent number: 10966968
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 6, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni
  • Compositions and methods for treatment of diabetic retinopathy
    Patent number: 10960087
    Abstract: The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: March 30, 2021
    Assignee: NOVARTIS AG
    Inventors: John Burnier, Thomas Gadek, Charles Semba
  • Combination therapy for proliferative diseases
    Patent number: 10953004
    Abstract: A combination product comprising: (A) a compound of formula (I) R-L-CO—X (I) wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and X is an electron withdrawing group; or a salt thereof; and (B) a compound of formula (X) where R1 is phenyl wherein said phenyl is substituted by lower alkyl unsubstituted or substituted by cyano; R3 is lower alkyl, such as methyl; and R4 is quinolinyl unsubstituted or substituted by halogen; or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: March 23, 2021
    Assignee: Avexxin AS
    Inventors: Berit Johansen, Astrid Jullumstrø Feuerherm
  • Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
    Patent number: 10946003
    Abstract: Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 16, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Taek Kwan Kwon, Kwang Young Lee, Ho Taek Im, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Method of treatment for reducing pain sensitization
    Patent number: 10940129
    Abstract: The present disclosure relates to the use of lipophilic mercaptans for the treatment of pain sensitization. The lipophilic mercaptans disclosed can be used to decrease the formation of protein-aldehyde adducts within nociceptive nerves, thereby reducing sensitization to pain.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 9, 2021
    Inventor: David Michael Ott
  • Methods for treating renal disease
    Patent number: 10940151
    Abstract: The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 9, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David J. Friedman, Martin R. Pollak
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10940154
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 9, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Intravenous baclofen formulations and treatment methods
    Patent number: 10933042
    Abstract: An intravenous baclofen solution is disclosed, along with methods of dosing and treatment therewith.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 2, 2021
    Assignees: Allaysis, LLC, Regents of the University of Minnesota
    Inventors: James C. Cloyd, Adolfo L. Gomez, Linda Krach, Robert L. Kriel, John Schrogie, Stephen John Tucker, Rob Tuohy
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10933070
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 2, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Polymorphic forms of ST-246 and methods of preparation
    Patent number: 10933050
    Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: March 2, 2021
    Assignee: SIGA TECHNOLOGIES INC.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. S. Anderson, William C. Weimers, Dylan Nelson, Tove′ C. Bolken, Dennis E. Hruby, Michael H. O'Neill, Gary Sweetapple, Kelley A. McCloughan
  • Polysaccharide-polyamine copolymer and use thereof in reducing low density lipolipoprotein (LDL) concentration in plasma
    Patent number: 10925893
    Abstract: Disclosed is a pharmaceutical composition for treating hypercholesterolemia. The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 23, 2021
    Inventor: Dazhi Yang
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 10919886
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: February 16, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Use of cannabidiol in the treatment of epilepsy
    Patent number: 10918608
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 16, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
  • Azetidine derivatives
    Patent number: 10918640
    Abstract: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: February 16, 2021
    Assignee: Vernalis (R&D) Ltd.
    Inventors: Stephen Roughley, Steven Walls, Terance Hart, Rachel Parsons, Paul Brough, Christopher Graham, Alba Macias
  • Compounds and methods of promoting myelination
    Patent number: 10918610
    Abstract: The invention is a method of treating a subject with primary progressive or secondary progressive multiple sclerosis. The method comprises administering an effect amount of Cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine or a pharmaceutically acceptable salt thereof to the subject.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Case Western Reserve University
    Inventors: Paul Tesar, Drew Adams, Steven B. Landau
  • Pyrimidine FGFR4 inhibitors
    Patent number: 10912774
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj